Company Profile
Advanced Bifurcation Systems, Inc. (ABS) is a US-based manufacturer of modular stent delivery systems for coronary bifurcation lesions, headquartered in Livermore, California. Founded in 2010 by Dr. Mehran Khorsandi (Chairman ＆ CEO) and Henry Bourang (President ＆ COO), the privately held company employs 17 people and has raised USD 31.8 million in total funding, including an USD 11 million Series A (December 2020) and an oversubscribed USD 20.8 million SAFE (December 2024). ABS is backed by institutional investors including Cedars Sinai Medical Center and Johnson ＆ Johnson.
Core Products ＆ Technologies
ABS Modular Bifurcation System
• ABS MD-SBA (Side-branch Access Stenting System): Provisional side-branch stenting configuration with independently movable dual-catheter platform; daughter catheter pre-threaded through a sleeve on the mother catheter for automatic orientation and alignment
• ABS MD-BI (Two Stent System): Mother-daughter stent (MDS) platform deploying stents in both main branch and side branch simultaneously; designed for complete carina coverage without stent deformity
• Dual-Catheter Architecture: Modular, independently movable monorail system mitigating wire wrap; alignment, phase shift, and orientation are automatic upon inflation
• Drug-Eluting Coating: Fourth-generation, non-durable polymer coating previously approved by the FDA; stent sizing based on Murray's law, eliminating need for additional completion balloons
Acquired Drug-Eluting Stent Portfolio (via Svelte Medical Systems)
• Svelte DES Platform: Drug-eluting coronary stents acquired from Svelte Medical Systems in October 2024; includes comprehensive US and international regulatory approvals and filings
• Regulatory Assets: US FDA Premarket Approval (PMA), Europe CE Mark, and Japan PMDA approvals for the acquired stent portfolio
• Strategic Synergy: Combined with ABS's bifurcation-focused delivery platform to accelerate global commercial presence in interventional cardiology; acquisition completion announced April 2026
Market Position ＆ Certifications
ABS holds a development-stage position in the dedicated coronary bifurcation device market, competing with Tryton Medical, Medtronic, Vesper Medical, and Poseidon Medical. Key strengths include:
• 15+ years of bifurcation technology innovation heritage
• First-in-human validation: 10 successful human implants across 3 international centers (Sao Paulo, Ahmadabad, Caracas) with 100% procedural success and peer-reviewed publications
• Regulatory progress: FDA Breakthrough Device Designation granted October 2023; clear pathway to full FDA approval targeted for 2027
• Intellectual property: 75+ issued US and international patents with Freedom to Operate opinion
• Institutional backing: Investors include Cedars Sinai Medical Center, Johnson ＆ Johnson, Brandon Holdings, and leading cardiologists
• Large addressable market: ~1.6 million procedures annually aggregating to ~USD 8+ billion
Corporate Timeline
2010 — Founded in Livermore, California by Dr. Mehran Khorsandi and Henry Bourang
2018 — Completed accelerator/incubator program; advanced prototype through bench testing and animal implants
2020 — Closed USD 11 million Series A financing
2023 — Granted FDA Breakthrough Device Designation for bifurcation stent delivery platform (October)
2024 — Acquired all assets of Svelte Medical Systems, adding FDA-approved drug-eluting coronary stent portfolio; completed oversubscribed USD 20.8 million SAFE financing (December)
2025 — Named Malia Chui and Susan Yashar to Board of Directors (January); expanded board with clinical and regulatory expertise
2026 — Announced completion of Svelte asset acquisition integration (April 27), positioning ABS among select global companies with FDA-approved drug-eluting coronary stent; targeting Series B financing to fund pathway through full FDA approval
Target Markets ＆ Applications
• Coronary Bifurcation Lesions: Primary indication for provisional and two-stent approaches in percutaneous coronary intervention (PCI)
• Left Main Coronary Artery Disease: Specially designed stent sizes and configurations for left main bifurcation deployments
• Complex Bifurcation Anatomy: Shallow-angle, distal, and multi-vessel bifurcations not optimally treated by conventional stent techniques
• Interventional Cardiology Labs: Tertiary hospitals, cardiac catheterization laboratories, and academic medical centers performing high-volume PCI
• Global Expansion: Regulatory and commercial development across the United States, Europe, Japan, and emerging markets
Contact Information
Global Headquarters
Address: 7419 Southfront Road, Livermore, California 94551, USA
Phone: +1 877 413 5845
Email: info@advancedbifurcation.com
Website: www.advancedbifurcation.com
